Nine Square Therapeutics Revenue and Competitors

Location

#9433

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Nine Square Therapeutics's estimated annual revenue is currently $2.5M per year.(i)
  • Nine Square Therapeutics's estimated revenue per employee is $77,500
  • Nine Square Therapeutics's total funding is $4M.

Employee Data

  • Nine Square Therapeutics has 32 Employees.(i)
  • Nine Square Therapeutics grew their employee count by 39% last year.

Nine Square Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Preclinical and Translational SciencesReveal Email/Phone
3
VP and Head ChemistryReveal Email/Phone
4
VP and Head BiologyReveal Email/Phone
5
VP and Head BiologyReveal Email/Phone
6
Senior Director, Head Program ManagementReveal Email/Phone
7
Project ManagerReveal Email/Phone
8
Senior ScientistReveal Email/Phone
9
Principal ScientistReveal Email/Phone
10
Associate ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Nine Square Therapeutics?

Nine Square Therapeutics, founded by ATP and leading scientists at UCSF, is discovering and delivering novel small-molecule therapeutics for movement disorders including Parkinson’s, ALS, essential tremors, and dyskinesias. Nine Square applies leading capabilities in computational chemistry, biophysics, and computational biology and a machine-learning-enabled cell profiling platform for target identification, chemical optimization, and patient stratification.

keywords:N/A

$4M

Total Funding

32

Number of Employees

$2.5M

Revenue (est)

39%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.3M323%N/A
#2
$3.6M32-11%N/A
#3
$5.6M32-22%N/A
#4
$3.4M32-63%$26M
#5
$2.5M32-27%$64M